Bio-Rad Laboratories Inc (NYSE:BIO) is set to release its Q2 2025 earnings on Jul 31, 2025. The consensus estimate for Q2 2025 revenue is $615.11 million, and the earnings are expected to come in at ...
Bio-Rad Laboratories (NYSE:BIO) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the ...
Bio-Rad Laboratories (BIO) has seen its stock edge upward over the past week, catching some attention among investors. Shares closed at $297.95, reflecting modest gains that contrast with longer-term ...
In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Bio-Rad Laboratories, Inc. stands amongst them. Bio-Rad Laboratories, Inc. (NYSE:BIO), a global ...
Artisan Partners, an investment management company, released its “Artisan Mid Cap Value Fund” first-quarter 2025 investor letter. A copy of the letter can be downloaded here. The growth stock trade ...
Throughout the last three months, 5 analysts have evaluated Bio-Rad Laboratories (NYSE:BIO), offering a diverse set of opinions from bullish to bearish. The following table summarizes their recent ...
Bio-Rad Laboratories, Inc. (NYSE:BIO) reported better-than-expected second-quarter financial results on Thursday. Bio-Rad Laboratories reported quarterly earnings of $2.61 per share which beat the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results